atypical haemolytic uraemic syndrome
Haematology · 2013–2023
5decisions
2medicines
2carried consumer input
14individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ravulizumab Atypical haemolytic uraemic syndrome (aHUS) in patients with active and progressing thrombotic microangiopathy. | Jul 2023 | Recommended with restriction | 14 individuals |
| eculizumab Prevention of atypical haemolytic uraemic syndrome (aHUS) recurrence in patients with end-stage renal disease due to aHUS who have received a renal allograft… | Mar 2018 | Not recommended | input received |
| eculizumab Treatment of atypical Haemolytic Uraemic Syndrome (aHUS). The PBAC is considering the continuation and discontinuation criteria for PBS-subsidised therapy. | Aug 2014 | Noted | no section in document |
| eculizumab Treatment of atypical haemolytic uraemic syndrome (aHUS) in patients with confirmed ADAMTS-13 activity >5% and ruled-out STEC infection, including those with… | Mar 2014 | Recommended with restriction | no section in document |
| eculizumab Treatment of atypical haemolytic uraemic syndrome (aHUS), a rare condition characterized by thrombotic microangiopathy affecting renal function and other… | Mar 2013 | Recommended | unclear |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.